Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Not yet recruiting 3

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3

Conditions

Lymphoma, Extranodal NK-T-Cell 3Leukemia, Myeloid, Acute 3Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Multiple Myeloma 1Lymphoma 1Leukemia, Myelomonocytic, Chronic 1Extensive Stage Lung Small Cell Cancer 1Carcinoma, Pancreatic Ductal 1Carcinoma 1

Interventions

selinexor 3pegaspargase 3Oxaliplatin 2Gemcitabine 2tislelizumab 1sugemalimab 1Thiotepa 1Radiotherapy 1Immune Checkpoint Inhibitors 1Azacitidine 1Asparaginase 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Not yet recruiting × Lymphoma, Extranodal NK-T-Cell × selinexor × Clear all
NCT07554482 2026-04-28

Selinexor Combined With Reduced-Dose Radiotherapy For Early-Stage Extranodal NK/T-Cell Lymphoma

Beijing Tongren Hospital

Phase 2 Not yet recruiting
34 enrolled
Lymphoid

Lymphoma, Extranodal NK-T-Cell

NCT07276698 2025-12-11

Clinical Study on Maintenance Therapy With Selinexor Combined With Azacitidine After Allogeneic Hematopoietic Stem Cell Transplantation for NK/T-cell Lymphoma

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Phase 2 Not yet recruiting
39 enrolled
Lymphoid

Lymphoma, Extranodal NK-T-Cell

NCT06573138 2024-08-27

Selinexor, Anti-PD-1 Antibody Plus Golidocitinib in R/R NKTCL

Ruijin Hospital

Phase 2 Not yet recruiting
18 enrolled
Lymphoid

Lymphoma, Extranodal NK-T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡